<DOC>
	<DOC>NCT01651299</DOC>
	<brief_summary>The primary objective of the study is to evaluate the responsiveness and utility of several clinical outcome assessments in the setting of copperhead snakebite. The secondary objective is to characterize the clinical course of signs, symptoms and impairment during the recovery phase of copperhead snakebite.</brief_summary>
	<brief_title>Copperhead Envenomation Observational Study</brief_title>
	<detailed_description>This observational study will document the patient's recovery from copperhead snakebite. All care provided will be at the discretion of the treating physician in accordance with the local standard of care.</detailed_description>
	<mesh_term>Poisoning</mesh_term>
	<mesh_term>Snake Bites</mesh_term>
	<criteria>Envenomation by a copperhead snake Presentation for care at a health care facility within 24 hrs of envenomation Envenomation on an extremity distal to the knee or elbow Clinical evidence of venom effect (limb swelling and/or tenderness) Enrollment can be completed within 48 hrs of envenomation prior to discharge Patient is willing and able to complete followup schedule of assessments Patient is able to read, comprehend and sign IRB approved informed consent Patient is able to read and comprehend written assessment tools Patient is at least 18 yrs old Patient is sober, competent and able to complete verbal and written informed consent Patient is pregnant or breastfeeding Patient is a prisoner Patient has distracting injury, condition with acute pain or functional impairment, and/or is unable to make a reliable selfreport of status Patient has had previous snake envenomation to any body area within 30 days prior to screening/enrollment, regardless of whether antivenom was administered Patient had an acute traumatic or medical event, surgery, or exacerbation of preexisting medical or surgical condition effecting the envenomated extremity within 30 days prior to screening/enrollment Patient has participated in a clinical study involving and investigational pharmaceutical product or device within 3 months prior to screening that may have impact on clinical outcomes of snakebite Patient has previously participated in this study Patient is, in the investigator's opinion, otherwise unsuitable for participation. Note: Treatment with antivenom prior to eligibility evaluation is not an exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>copperhead snake envenomation</keyword>
</DOC>